Breastcancer.org Podcast

335 Episodes

1. Experimental Talazoparib Seems Better Than Chemotherapy for Metastatic HER2-Negative Disease in Women With a BRCA Mutation

   Published: 15/01/2020
2. SABCS 2019: Five More Years of Femara Seems to Reduce Breast Cancer Recurrence Risk for Some Women

   Published: 09/01/2020
3. SABCS 2019: MRI Finds Breast Cancers Earlier Than Mammography in Women With Strong Family History

   Published: 08/01/2020
4. Diarrhea -- Breast Cancer Treatment Side Effects

   Published: 08/01/2020
5. SABCS 2019: Arimidex for Breast Cancer Prevention: Benefits Last Nearly 6 Years After Treatment Ends

   Published: 08/01/2020
6. Does Immunotherapy Before Breast Cancer Surgery Offer Benefits? – Heard in the Halls: Voices From the 2019 SABCS

   Published: 07/01/2020
7. What My Patients Are Asking: What Is the Lung Inflammation Side Effect Caused by CDK4/6 Inhibitors?

   Published: 20/12/2019
8. World-Record Swim 1 Year After Treatment

   Published: 17/12/2019
9. Mets, Sex, and Side Effects – Heard in the Halls: Voices From the 2019 SABCS

   Published: 17/12/2019
10. Beneath the Breast – Heard in the Halls: Voices From the 2019 SABCS

    Published: 17/12/2019
11. GRASP: Empowering Patients With Knowledge – Heard in the Halls: Voices From the 2019 SABCS

    Published: 13/12/2019
12. Why Sexual Health Is Crucial for People With Metastatic Breast Cancer – Heard in the Halls: Voices From the 2019 SABCS

    Published: 13/12/2019
13. Chemo Brain Update: Cancer-Related Cognitive Decline

    Published: 22/11/2019
14. Sharing Knowledge: Pairing Experts With Patient Advocates

    Published: 08/11/2019
15. How to Ease Aromatase Inhibitor-Related Pain

    Published: 21/10/2019
16. Breast Cancer Research Highlights -- Heard in the Halls: Voices From ESMO 2019

    Published: 18/10/2019
17. Where Are We With Immunotherapy for Breast Cancer? ESMO 2019 Coverage

    Published: 18/10/2019
18. "CDK4/6 Inhibitor Plus Hormonal Therapy Should Be First Treatment for Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer" ESMO 2019 Coverage

    Published: 14/10/2019
19. Immunotherapy to Treat Metastatic HER2-Positive Breast Cancer: ESMO 2019 Coverage

    Published: 14/10/2019
20. Verzenio Plus Faslodex Improves Survival in Metastatic Hormone-Receptor-Positive, HER2-Negative Breast Cancer, Regardless of Menopausal Status

    Published: 08/10/2019